Caris Life Sciences,�Inc. CAI
31.98
(0.29)
(0.90%)
as of 25 Sep
- Market cap
- $9.1B
- P/E
- 85.1×
Follow CAI
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+6 more quarters Free account |
0.00 | 0.00 | 0.00 | 47.41 |
P/S ratio |
13.75 | 5.56 | 5.57 | 5.09 | |
P/FCF ratio |
0.00 | 67.44 | 40.92 | 40.67 | |
P/Operating CF |
136.70 | 100.74 | 153.67 | 177.02 | |
P/B ratio |
17.84 | 7.81 | 8.51 | 8.52 | |
Price to Tangible BV |
18.59 | 8.09 | 8.80 | 8.81 | |
EV/Sales |
13.13 | 5.04 | 5.08 | 4.69 | |
EV/EBITDA |
0.00 | 50.81 | 32.37 | 25.78 | |
EV/Operating CF |
(14,932.13) | 49.19 | 31.28 | 27.53 | |
EV/FCF |
(582.10) | 61.14 | 37.34 | 37.44 | |
Quick Ratio |
9.11 | 7.17 | 6.35 | 4.75 | |
Current Ratio |
9.93 | 7.85 | 7.05 | 5.53 | |
Net Debt/EBITDA |
(9.52) | (4.51) | (34.07) | (11.85) | |
Debt/Assets |
38.24% | 33.67% | 32.83% | 31.97% | |
Debt/Equity |
0.79 | 0.66 | 0.64 | 0.66 | |
Asset Turnover |
1.26 | 1.44 | 1.56 | 0.91 | |
Operating CF/Net income |
2.57 | 0.78 | (64.46) | (44.70) | |
Capex/Depreciation |
(0.97) | (1.04) | (1.34) | (3.23) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.97% | 10.87% | 14.49% | 12.27% | |
Selling, General and Administrative Expense of Revenue |
43.00% | 34.37% | 48.46% | 45.62% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
6.30% | 4.56% | 7.34% | 8.43% | |
Graham Net Nets |
0.04 | 0.10 | 0.09 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 4.21 | |
Earnings Yield |
(41.85%) | (38.81%) | (42.46%) | 2.11% | |
Free Cash Flow Yield |
(0.16%) | 1.48% | 2.44% | 2.46% | |
Revenue per Share |
0.77 | 1.75 | 0.77 | 0.93 | |
Operating CF per Share |
0.22 | 0.27 | 0.12 | 0.10 | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.08) | |
Free Cash Flow per Share |
0.20 | 0.24 | 0.08 | 0.02 | |
Cash per Share |
2.68 | 4.79 | 2.91 | 2.80 | |
Shareholders Equity per Share |
1.70 | 3.45 | 2.10 | 2.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.70 | 3.45 | 2.10 | 2.09 | |
Free Cash Flow |
55.33 | 39.69 | 22.53 | 6.40 | |
Working Capital |
768.22 | 870.66 | 870.28 | 866.39 | |
Capital Expenditures |
(7.09) | (5.09) | (10.34) | (22.07) | |
Net Current Asset Value |
348.04 | 449.44 | 445.28 | 419.94 | |
EV/EBIT |
0.00 | 90.66 | 42.55 | 30.28 | |
Capex to Sales |
0.03 | 0.02 | 0.05 | 0.08 | |
Net Profit Margin |
11.22% | 19.63% | (0.24%) | (0.24%) | |
Price to Operating Income |
0.00 | 100.00 | 46.63 | 32.89 | |
| Other line items | |||||
Average Receivables |
— | — | 89.38 | 83.89 | |
Average Payables |
— | — | 48.80 | 57.36 | |
Average Inventory |
— | — | 57.93 | 82.20 | |
Average Assets |
492.29 | 562.83 | 581.19 | 1,092.34 | |
Average Common Equity |
— | — | (952.67) | 522.32 |
Columns are period end dates